Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial

被引：28

作者：

Araujo, John C.

Trudel, Geralyn C.

Saad, Fred

Armstrong, Andrew J.

Yu, Evan Y.

Bellmunt, Joaquim

Wilding, George

McCaffrey, John

Serrano, Sergio V.

Matveev, Vsevolod

Efstathiou, Eleni

Oudard, Stephane

Morris, Michael J.

Sizer, Bruce

Goebell, Peter J.

De Bono, Johann Sebastian

Paliwal, Prashni

Durham, Susan

Cheng, Shinta

Logothetis, Christopher

机构：

[1] Univ Washington, Seattle, WA 98195 USA

[2] Seattle Canc Care Alliance, Seattle, WA USA

[3] Univ Hosp Mar, IMIM, Barcelona, Spain

[4] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[5] ICORG, Dublin, Ireland

[6] Hosp Canc Barretos, Sao Paulo, Brazil

[7] NN Blokhin Canc Res Ctr, Moscow, Russia

[8] Univ Athens, Dept Clin Therapeut, Athens, Greece

[9] Georges Pompidou European Hosp, Dept Med Oncol, Paris, France

[10] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, New York, NY 10021 USA

[11] Essex Cty Hosp, Colchester, Essex, England

[12] Univ Erlangen Nurnberg, Dept Urol, D-91054 Erlangen, Germany

[13] Royal Marsden Hosp, Inst Canc Res, Sutton, Surrey, England

[14] Bristol Myers Squibb Co, Wallingford, CT 06492 USA

[15] Bristol Myers Squibb Co, Princeton, NJ USA

[16] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Onol, Houston, TX 77030 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 06期

关键词：

D O I：

10.1200/jco.2013.31.6_suppl.lba8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA8

引用

页数：1

共 50 条

[31] Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC).
Maughan, Benjamin Louis
Suzman, Daniel L.
Nadal, Rosa
Bassi, Sunakshi
Schweizer, Michael Thomas
Antonarakis, Emmanuel S.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
[32] Updated results: A phase InIa randomized trial of radium-223+docetaxel versus docetaxel in patients with castration-resistant prostate cancer and bone metastases.
Morris, Michael J.
Loriot, Yohann
Sweeney, Christopher
Fizazi, Karim
Ryan, Charles J.
Shevrin, Daniel H.
Antonarakis, Emmanuel S.
Reeves, John
Chandrawansa, Kumari
Kornacker, Martin
Higano, Celestia S.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[33] CAPItello-280: A phase III study of capivasertib and docetaxel versus placebo and docetaxel in metastatic castration-resistant prostate cancer.
Crabb, Simon J.
Ye, Ding-Wei
Uemura, Hirotsugu
Morris, Thomas
Gresty, Christopher
Logan, Jill
Rooney, Claire
Foxley, Andrew
Carducci, Michael Anthony
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[34] Phase I trial with a combination of docetaxel and 153Sm- EDTMP in patients (pts) with castration-resistant metastatic prostate cancer (mCRPC)
Eisenberger, M. A.
Lin, J.
Sinibaldi, V. J.
Carducci, M. A.
Denmeade, S.
DeWeese, T.
Song, D.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[35] Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer
Chi, K. N.
Hotte, S. J.
Yu, E.
Tu, D.
Eigl, B.
Tannock, I.
Saad, F.
North, S.
Powers, J.
Eisenhauer, E.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[36] Phase 2 randomized trial of ModraDoc006/r, oral docetaxel plus ritonavir, versus intravenous docetaxel in metastatic castration resistant prostate cancer (mCRPC).
Vaishampayan, Ulka N.
Keessen, Marianne
Shore, Neal D.
Heath, Elisabeth I.
Dreicer, Robert
Buchler, Tomas
Arkosy, Peter Ferenc
Csoszi, Tibor
Wiechno, Pawel J.
Kopyltsov, Evgeny
Kholtobin, Denis
Orlov, Sergey
Nosov, Aleander
Varlamov, Sergey
Vogelzang, Nicholas J.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[37] Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel
Nuhn, Philipp
Vaghasia, Ajay M.
Goyal, Jatinder
Zhou, Xian C.
Carducci, Michael A.
Eisenberger, Mario A.
Antonarakis, Emmanuel S.
BJU INTERNATIONAL, 2014, 114 (6B) : E11 - E17
[38] Updated overall survival (OS) analysis for ProCAID: A randomized, double-blind, placebo-controlled phase II trial of capivasertib with docetaxel versus docetaxel alone in metastatic castration-sensitive prostate cancer (mCRPC).
Crabb, Simon J.
Griffiths, Gareth Owen
Dunkley, Denise
Downs, Nichola
Ellis, Mary
Radford, Mike
Light, Michelle
Northey, Josh
Whitehead, Amy
Wilding, Sam
Rooney, Claire
Salinas-Souza, Carolina
Birtle, Alison Jane
Khoo, Vincent
Jones, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[39] Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Ning, Yang-Min
Gulley, James L.
Arlen, Philip M.
Woo, Sukyung
Steinberg, Seth M.
Wright, John J.
Parnes, Howard L.
Trepel, Jane B.
Lee, Min-Jung
Kim, Yeong Sang
Sun, Haihao
Madan, Ravi A.
Latham, Lea
Jones, Elizabeth
Chen, Clara C.
Figg, William D.
Dahut, William L.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (12) : 2070 - 2076
[40] Aflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): Results from the multinational phase III trial (VENICE)
Tannock, Ian
Fizazi, Karim
Ivanov, Sergei
Karlsson, Camilla Thellenberg
Flechon, Aude
Skoneczna, Iwona Anna
Orlandi, Francisco Jorquera
Gravis, Gwenaelle
Matveev, Vsevolod B.
Bavbek, Sevil E.
Gil, Thierry
Viana, Luciano S.
Aren, Osvaldo Rudy
Karyakin, Oleg
Elliott, Tony
Birtle, Alison J.
Magherini, Emmanuelle
Hatteville, Laurence
Tombal, Bertrand
Rosenthal, Mark
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)

← 1 2 3 4 5 →